At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 80 enrolled
Drug / intervention
BAC treatment +1 moredrug
Likely dose
BAC treatment 30 gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Vehicle-Controlled, Parallel, Phase II Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia
In Brief
A Phase 2 clinical trial evaluating BAC treatment and Matched vehicle for Alzheimer's Disease or Vascular Dementia. Completed, enrolled 80 participants across 10 sites.
Detailed Summary
A Randomized, Double-Blind, Vehicle-Controlled, Parallel, Phase II Study to Evaluate Efficacy and Safety of BAC in Patient with Alzheimer's Disease or Vascular Dementia
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease or Vascular Dementia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedSep 2016
Enrollment StartDec 2016
Primary CompletionNov 2018
TodayJul 2026
First PostedSep 1, 2016
Enrollment StartDec 1, 2016
Primary CompletionNov 1, 2018
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 9.8 years ago
Interventions
BAC treatmentdrug
BAC, topical application on external nasal skin, scalp, and neck, 2 times daily, 30 g/day for 12 weeks
Matched vehicledrug
BAC matched vehicle, topical application on external nasal skin, scalp, and neck, 2 times daily, 30 g/day for 12 weeks